Exosome‐Functionalized Self‐Carrier Enzyme‐Like/Drug With Triple Amplified Anti‐Oxidative Stress for Synergistic Depression Therapy
Small,
Год журнала:
2025,
Номер
unknown
Опубликована: Апрель 22, 2025
Abstract
Depression,
a
severe
disorder
affecting
both
physical
and
mental
health,
is
commonly
treated
with
first‐line
antidepressants,
which
often
exhibit
limited
efficacy
due
to
poor
penetration
of
the
blood‐brain
barrier
(BBB)
significant
side
effects,
thus
requiring
exploitation
biocompatible
effective
treatments.
Recent
studies
suggest
that
depression
closely
linked
an
imbalance
in
oxidative
stress
subsequent
inflammatory
responses.
Antioxidant
therapies
targeting
are
therefore
emerging
as
promising
strategies.
In
this
study,
exosome‐functionalized
geniposide
(GEN)
self‐carried
Prussian
blue
(PB)
nanotherapeutic
approach
fabricated
realize
efficient
BBB
for
synergistic
therapy.
The
porous
PB
carrier
possesses
multi‐enzyme
capabilities,
can
effectively
scavenge
accumulated
ROS,
protecting
slightly
acidic
environment
released
GEN
from
oxidation,
subsequently
works
simultaneously
activate
Nrf2‐ARE
pathway,
enhancing
body's
defense
mechanisms
synergistically.
triple‐amplified
anti‐oxidant
strategy
nanomaterial
shown
mitigate
microglial
activation
reduction
neuroplasticity,
ultimately
alleviating
pathological
markers
depression.
Overall,
constructed
nanomaterials
underscore
therapeutic
potential
anti‐oxidative
removal
ROS
pathway
treatment
Язык: Английский
Protective Potential of Sodium-Glucose Cotransporter 2 Inhibitors in Internal Medicine (Part 1)
Innovative medicine of Kuban,
Год журнала:
2024,
Номер
4, С. 126 - 135
Опубликована: Ноя. 15, 2024
Sodium-glucose
cotransporter
2
inhibitors
(SGLT2i)
have
emerged
as
a
revolutionary
class
of
drugs
with
far-reaching
protective
effects
in
multiple
organs.
The
potential
SGLT2i
is
much
broader
than
that
the
classical
concept
glucose
control
and
consists
an
entire
conglomerate
associated
pleiotropic
effects.
This
study
aims
to
provide
descriptive
review
therapeutic
SGLT2i.
first
part
literature
examined
use
cardiology
nephrology.
represents
innovative
approach
improving
patients’
quality
life
course
heart
failure
chronic
kidney
disease,
regardless
left
ventricular
ejection
fraction
type
diabetes.
Язык: Английский